Patient Portal

Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor, Neurology
Director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)

Specialty Areas

Dementia
Neurology - Adult
Alzheimer's Disease
Memory Disorders and Diagnosis

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Alzheimer's disease, dementia, geriatric neurology, neurodegenerative diseases, mild cognitive impairment, aging, cognitive function

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985

Education

Education

Clinical Fellowship: Dementia, Washington University School of Medicine, St. Louis, Missouri 2005
Residency: Neurology, Barnes-Jewish Hospital, St. Louis, Missouri 2004
Medical Degree: Case Western Reserve University School of Medicine, Cleveland, Ohio 2000
B.S.: Biology, Washington University, St. Louis, Missouri 1996
B.S.: Electrical Engineering, Washington University, St. Louis, Missouri 1996

Publication & Research

Publication & Research

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer's Disease.
Barthélemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ
Front Aging Neurosci. 2019; 11121. doi: 10.3389/fnagi.2019.00121.

PMID:
    31178717
    [PubMed]
Related citations


Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G
Nat Commun. 2019 May 20; 10(1)2240. doi: 10.1038/s41467-019-10152-w.

PMID:
    31110178
    [PubMed - indexed for MEDLINE]
Related citations


Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.
Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B
J Prev Alzheimers Dis. 2019; 6(3)169-173. doi: 10.14283/jpad.2019.21.

PMID:
    31062827
    [PubMed - in process]
Related citations


Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B
J Prev Alzheimers Dis. 2019; 6(3)157-163. doi: 10.14283/jpad.2019.14.

PMID:
    31062825
    [PubMed - in process]
Related citations


The structure of amyloid-β dimers in Alzheimer's disease brain: a step forward for oligomers.
Bateman RJ, Mawuenyega KG, Wildburger NC
Brain. 2019 May 1; 142(5)1168-1169. doi: 10.1093/brain/awz082.

PMID:
    31032843
    [PubMed - in process]
Related citations


The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.
Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M
Mol Psychiatry. 2019 Mar 21; doi: 10.1038/s41380-019-0404-6.

PMID:
    30899092
    [PubMed - as supplied by publisher]
Related citations


Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.
Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J, Dominantly Inherited Alzheimer Network.
Brain. 2019 May 1; 142(5)1429-1440. doi: 10.1093/brain/awz050.

PMID:
    30897203
    [PubMed - in process]
Related citations


Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.
Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS
Alzheimers Dement (Amst). 2019 Dec; 11180-190. doi: 10.1016/j.dadm.2018.12.008.

PMID:
    30847382
    [PubMed]
Related citations


Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM, Dominantly Inherited Alzheimer Network.
Alzheimers Dement. 2019 May; 15(5)655-665. doi: 10.1016/j.jalz.2018.12.019.

PMID:
    30846386
    [PubMed - in process]
Related citations


Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset.
Wang G, Coble D, McDade EM, Hassenstab J, Fagan AM, Benzinger TLS, Bateman RJ, Morris JC, Xiong C, Dominantly Inherited Alzheimer Network (DIAN).
Alzheimers Dement. 2019 Apr; 15(4)506-514. doi: 10.1016/j.jalz.2018.12.008.

PMID:
    30773445
    [PubMed - in process]
Related citations


Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS
Brain. 2019 Apr 1; 142(4)1063-1076. doi: 10.1093/brain/awz019.

PMID:
    30753379
    [PubMed - in process]
Related citations


Persistent metabolic youth in the aging female brain.
Goyal MS, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL, Morris JC, Raichle ME, Vlassenko AG
Proc Natl Acad Sci U S A. 2019 Feb 19; 116(8)3251-3255. doi: 10.1073/pnas.1815917116.

PMID:
    30718410
    [PubMed - indexed for MEDLINE]
Related citations


Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M, Dominantly Inherited Alzheimer Network.
Nat Med. 2019 Feb; 25(2)277-283. doi: 10.1038/s41591-018-0304-3.

PMID:
    30664784
    [PubMed - indexed for MEDLINE]
Related citations


Seizures as an early symptom of autosomal dominant Alzheimer's disease.
Vöglein J, Noachtar S, McDade E, Quaid KA, Salloway S, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A, Dominantly Inherited Alzheimer Network.
Neurobiol Aging. 2019 Apr; 7618-23. doi: 10.1016/j.neurobiolaging.2018.11.022.

PMID:
    30616208
    [PubMed - in process]
Related citations


Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease.
Wang G, Xiong C, McDade EM, Hassenstab J, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Gordon BA, Morris JC, Li Y, Bateman RJ, Dominantly Inherited Alzheimer Network (DIAN).
Alzheimers Dement (N Y). 2018; 4669-676. doi: 10.1016/j.trci.2018.10.009.

PMID:
    30569014
    [PubMed]
Related citations


Protein production is an early biomarker for RNA-targeted therapies.
Self WK, Schoch KM, Alex J, Barthélemy N, Bollinger JG, Sato C, Cole T, Kordasiewicz HB, Swayze E, Bateman RJ, Miller TM
Ann Clin Transl Neurol. 2018 Dec; 5(12)1492-1504. doi: 10.1002/acn3.657.

PMID:
    30564616
    [PubMed]
Related citations


Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.
Bussy A, Snider BJ, Coble D, Xiong C, Fagan AM, Cruchaga C, Benzinger TLS, Gordon BA, Hassenstab J, Bateman RJ, Morris JC, Dominantly Inherited Alzheimer Network.
Neurobiol Aging. 2019 Mar; 7542-50. doi: 10.1016/j.neurobiolaging.2018.10.011.

PMID:
    30530186
    [PubMed - in process]
Related citations


CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.
Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C, Dominantly Inherited Alzheimer Network., Alzheimer's Disease Neuroimaging Initiative.
EMBO Mol Med. 2018 Dec; 10(12)pii: e9712. doi: 10.15252/emmm.201809712.

PMID:
    30482868
    [PubMed - in process]
Related citations


The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, Nordberg A, White LR, Nielsen HM, Dominantly Inherited Alzheimer Network (DIAN).
Acta Neuropathol Commun. 2018 Nov 26; 6(1)130. doi: 10.1186/s40478-018-0624-z.

PMID:
    30477568
    [PubMed - indexed for MEDLINE]
Related citations


Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.
Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR Jr, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TLS, Dominantly Inherited Alzheimer Network.
Alzheimers Dement (Amst). 2018; 10669-677. doi: 10.1016/j.dadm.2018.08.012.

PMID:
    30417072
    [PubMed]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2018:

Company Name: C2N Diagnostics

Royalties: $10,000 - $19,999

Equity: Yes

Consulting/Advisory Board: $40,000 - $59,999

Speaker Fees:

Reporting Date: May 01, 2019